Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach

Future Journal of Pharmaceutical Sciences

Table 2 The predicted pIC₅₀ of the newly designed series of newly designed EGFR^WT inhibitors

S/No	ATSC1p	GATS1s	GATS8s	SpMin8_Bhm	RDF65e	P1e	Predicted pIC₅₀
SFD1	0.908	0.989	0.993	0.07	0.312	0.951	11.093
SFD2	0.821	0.222	0.606	0.072	0.32	0.959	10.319
SFD3	0.873	0.307	0.296	0.098	0.398	0.97	10.729
SFD4	0.793	0.126	0.082	0.118	0.179	0.945	10.286
SFD5	0.811	0.382	0.391	0.991	0.558	1	7.7469
SFD6	0.821	0.222	0.594	0.076	0.397	0.946	10.335
SFD7	0.793	0.126	0.465	0	0.118	0.872	10.143
SFD8	0.816	0	0.494	0.069	0.672	0.946	10.339
SFD9	0.902	0.216	0.596	0.067	0.194	0.938	10.264
SFD10	0.816	0.003	0.341	0.081	0.56	0.214	8.298